enGene (NASDAQ:ENGN) Stock Rating Raised to Strong-Buy at Jefferies Financial Group

enGene (NASDAQ:ENGN) was upgraded by research analysts at Jefferies Financial Group to a “strong-buy” rating in a research report issued on Tuesday, Zacks reports.

A number of other research analysts have also commented on the company. Morgan Stanley lowered enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 target price for the company. in a research note on Thursday, June 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of enGene in a report on Wednesday, August 12th. Citigroup reiterated a “market perform” rating on shares of enGene in a research note on Wednesday, September 9th. HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of enGene in a report on Tuesday, September 8th. Finally, Wall Street Zen upgraded enGene from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $11.05.

enGene Stock Down 4.1%

NASDAQ ENGN opened at $1.63 on Tuesday. The company’s fifty day moving average is $1.84 and its two-hundred day moving average is $2.90. enGene has a 52-week low of $1.40 and a 52-week high of $12.25. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.21 and a current ratio of 10.21.

enGene (NASDAQ:ENGN) last announced its quarterly earnings data on Tuesday, September 8th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). On average, sell-side analysts anticipate that enGene will post -1.81 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Perceptive Advisors LLC lifted its holdings in enGene by 179.8% in the fourth quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock valued at $52,998,000 after buying an additional 3,771,840 shares during the period. Siren L.L.C. grew its holdings in enGene by 57.5% during the 1st quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock worth $35,774,000 after acquiring an additional 1,916,895 shares during the period. Cormorant Asset Management LP grew its holdings in enGene by 72.1% during the 4th quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock worth $36,120,000 after acquiring an additional 1,676,405 shares during the period. Omega Fund Management LLC raised its position in shares of enGene by 66.5% during the 4th quarter. Omega Fund Management LLC now owns 876,357 shares of the company’s stock valued at $7,914,000 after acquiring an additional 350,000 shares during the last quarter. Finally, SR One Capital Management LP bought a new stake in shares of enGene during the 2nd quarter valued at $1,293,607. Institutional investors own 64.16% of the company’s stock.

Key enGene News

Here are the key news stories impacting enGene this week:

• Positive Sentiment: Analysts cited in the report have an average price target of $11.05 for enGene, substantially above the recent trading level. This suggests significant potential upside if the company executes on its development plans and investor sentiment improves. enGene Holdings Inc. Stock Has Average Target Price of $11.05
• Neutral Sentiment: The article does not identify a new clinical, regulatory, or financial catalyst. As a result, the analyst target alone may have limited immediate influence on trading, particularly given enGene’s early-stage biotechnology profile.
• Negative Sentiment: Recent investor concerns include enGene’s quarterly earnings miss, with reported loss per share of $0.47 versus the $0.43 consensus estimate, as well as continued losses expected for the full year. The shares remain below their 50-day and 200-day moving averages, indicating persistent downward momentum despite the high analyst target.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.